S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adr3963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Wen Luo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China. Hauptthemen laut MEDLINE: Calgranulin B, Calgranulin A, Myelopoiesis, Bone Marrow. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
S100A8/A9 plays a critical role in the formation of an immunosuppressive tumor microenvironment. Therefore, it is important to identify inhibitors targeting S100A8/A9 to enhance antitumor immunity. However, systemic targeting of S100A8/A9 in clinical trials has shown minimal effects. Understanding the reasons underlying this underperformance is important for developing drugs targeting S100A8/A9 that could effectively reverse the immunosuppressive tumor microenvironment. In this study, using hematopoietic system–specific conditional knockout mice in heterotopic models of lung and colon cancer and systemic pharmacological interference, we demonstrated that S100A8/A9 perturbation in the hematopoietic system accelerates tumor progression by attenuating T cell–mediated antitumor immunity. Mechanistically, S100A8/A9 perturbation triggered myeloid-biased differentiation in the bone marrow by promoting the production of abnormal granulocyte-monocyte progenitors. The local release of S100A8/A9 inhibitors using a tumor-targeted drug delivery system exhibited antitumor potential by avoiding myelopoiesis-promoting effects. These findings reveal a mechanism underlying the limited efficacy of systemic S100A8/A9 inhibition and propose a targeted strategy to enhance antitumor effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China.
- Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, P.R. China.
- Department of Respiration, Hospital of the Coast Guard Corps of the Chinese People's Armed Police Force, Zhejiang 314000, P.R. China.
- Department of Hematology and Oncology, 988th Hospital of Joint Logistic Support Force of PLA, Zhengzhou 450042, P.R. China.
- Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing 400016, P.R. China.
- School of Life Science, Chongqing University, Chongqing 400044, P.R. China.
ORCID-Profile: Wen Luo, Xingxing Su, Qiao Zhang, Zheng Jin, Yang Fei, Guitong Lv, Mengyi Li, Haoran Zha, Ji Liu, Zhong Luo, Haixia Long, Bo Zhu
Zitieren
APA
Luo, W., Su, X., Zhang, Q., Wang, Z., Jin, Z., Li, Y., Fei, Y., Zeng, D., Zeng, X., Lv, G., Li, M., Huang, J., Zha, H., Liu, J., Luo, Z., Long, H., & Zhu, B. (2025). S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr3963
Vancouver
Luo W, Su X, Zhang Q, Wang Z, Jin Z, Li Y, et al. S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adr3963
BibTeX
@article{Luo2025,
author = {Luo, Wen and Su, Xingxing and Zhang, Qiao and Wang, Zhongyu and Jin, Zheng and Li, Yanan and Fei, Yang and Zeng, Dong and Zeng, Xianghua and Lv, Guitong and Li, Mengyi and Huang, Jiani and Zha, Haoran and Liu, Ji and Luo, Zhong and Long, Haixia and Zhu, Bo},
title = {S100A8/A9 perturbation in bone marrow blunts antitumor immunity by promoting protumorigenic myelopoiesis in mouse models},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adr3963}
}
EUVIMED